🇺🇸 FDA
Patent

US 8273797

Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde

granted A61KA61K31/145A61K31/15

Quick answer

US patent 8273797 (Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/145, A61K31/15, A61K31/245, A61K31/277